Pacylex

About:

Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.

Twitter/X: pacylex

Top Investors: U.S. Department of Defense, VA Angels, Greenfire Bio

Description:

Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers. The company is developing a small molecule, oral chemotherapeutic, PCLX-001, to exploit this cancer mechanism by turning on selective lethality, apoptosis, in these cancer cells. The company's approach exploits a previously-unknown therapeutic target in cancer, making the drug a first-in-kind therapy. The diagnostic technology identifies those patients who will benefit from the drug, sparing many patients needless treatment. Pacylex Pharmaceuticals was founded on 2012 and is headquartered in Edmonton, Alberta, Canada.

Total Funding Amount:

$12.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Edmonton, Alberta, Canada

Founded Date:

2012-01-01

Contact Email:

info(AT)pacylex.com

Founders:

John Mackey, Luc Berthiaume, Ryan Heit

Number of Employees:

1-10

Last Funding Date:

2022-10-11

IPO Status:

Private

Industries: